[go: up one dir, main page]

CA2526853A1 - Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 - Google Patents

Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 Download PDF

Info

Publication number
CA2526853A1
CA2526853A1 CA002526853A CA2526853A CA2526853A1 CA 2526853 A1 CA2526853 A1 CA 2526853A1 CA 002526853 A CA002526853 A CA 002526853A CA 2526853 A CA2526853 A CA 2526853A CA 2526853 A1 CA2526853 A1 CA 2526853A1
Authority
CA
Canada
Prior art keywords
virus
antigen
thioaptamer
immune response
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002526853A
Other languages
English (en)
Inventor
David G. Gorenstein
Bruce A. Luxon
Norbert K. Herzog
Allan Barrett
Xian Bin Yang
Judith F. Aronson
David Beasley
Robert E. Shope (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2526853A1 publication Critical patent/CA2526853A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002526853A 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 Abandoned CA2526853A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47288803P 2003-05-23 2003-05-23
US60/472,888 2003-05-23
PCT/US2004/016246 WO2005018537A2 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Publications (1)

Publication Number Publication Date
CA2526853A1 true CA2526853A1 (fr) 2005-03-03

Family

ID=34215796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002526853A Abandoned CA2526853A1 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Country Status (3)

Country Link
EP (1) EP1667729A4 (fr)
CA (1) CA2526853A1 (fr)
WO (1) WO2005018537A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
AU2006243334A1 (en) 2005-05-04 2006-11-09 Noxxon Pharma Ag Novel use of spiegelmers
WO2010129666A1 (fr) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Immunité chimiquement programmable
CN112961860A (zh) * 2013-03-14 2021-06-15 私募蛋白质体公司 结合il-6的适体及其在治疗或诊断il-6介导的疾患中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (fr) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
EP0855184A1 (fr) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US6725526B2 (en) * 2002-01-14 2004-04-27 Hitachi Global Storage Technologies Netherlands B.V. Method of forming microsuspension assemblies for direct access storage devices
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
CA2749227A1 (fr) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
EP1635693A2 (fr) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors

Also Published As

Publication number Publication date
WO2005018537A3 (fr) 2005-05-26
EP1667729A4 (fr) 2007-10-17
WO2005018537A2 (fr) 2005-03-03
EP1667729A2 (fr) 2006-06-14

Similar Documents

Publication Publication Date Title
US9567579B2 (en) Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US20060121489A1 (en) High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
KR101360955B1 (ko) 비서열 상보적 항바이러스 올리고뉴클레오티드
Tavitian In vivo imaging with oligonucleotides for diagnosis and drug development
JP4176466B2 (ja) 前立腺特異的膜抗原に対する核酸リガンド
JP2013507905A5 (fr)
JP2010536335A (ja) 活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド
CN101809154A (zh) C5a结合核酸
CN113249380B (zh) 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用
Stephens The emerging potential of Aptamers as therapeutic agents in infection and inflammation
CN1390253A (zh) 高级核酸型结构
JP2023099157A (ja) Ａｄａｍｔｓ５に対するアプタマー及びその使用
CA2526853A1 (fr) Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1
JPWO2020123816A5 (fr)
JP2023058675A (ja) ウイルス感染及び活性抑制方法
CN117821463A (zh) 一种特异性抗病毒增殖的核酸及其应用
CN103597075A (zh) 用于选择性地杀伤细胞的生物活性核苷酸分子、其用途及应用试剂盒
Srivastava “Phage Display” a promising tool for viral diseases
CA2907636C (fr) Aptamere pour il-17 et utilisation de celui-ci
Du Designing 3D Wireframe DNA Nanoparticles for Programmable Innate Immune Activation
US20050118611A1 (en) Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
CN118497207A (zh) 靶向eb病毒的核酸适配体及其应用
EP4294926A1 (fr) Composés pour inhiber l'interaction du sars-cov-2 avec une protéine humaine ace2
WO2020204151A1 (fr) Aptamère dirigé contre fgf9 et son utilisation
Tavitian In vivo imaging with oligonucleotides for diagnosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued